-
06:17:54 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

SRRA Stock News

05/12/22 10:00 AM
Nasdaq : SRRA
clinical triallow float
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association. “We are excited and honored to have the MOMENTUM data selected for an oral presentation at EHA...
RHEA-AI
neutral
05/05/22 4:05 PM
Nasdaq : SRRA
low float
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company’ s Board of Directors, under Sierra Oncology’ s 2018 Equity Inducement Plan. The options have an exercise price of $54.61 per share,...
RHEA-AI
very positive
04/13/22 7:53 AM
Nasdaq : SRRA
low float
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Sierra Oncology, Inc. to GlaxoSmithKline plc for $55.00 per share in cash is fair to Sierra Oncology shareholders. Halper Sadeh encourages Sierra Oncology shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at...
RHEA-AI
neutral
04/13/22 2:05 AM
Nasdaq, NYSE : SRRA, GSK
acquisitionlow float
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
GlaxoSmithKline plc and Sierra Oncology, Inc today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California- based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate...
RHEA-AI
positive
04/06/22 6:00 PM
Nasdaq : SRRA
low float
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company’ s Board of Directors, under Sierra Oncology’ s 2018 Equity Inducement Plan. The options have an exercise price of $33.76 per share,...
RHEA-AI
very positive
03/11/22 7:00 AM
Nasdaq : SRRA
conferenceslow float
Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32 nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview...
RHEA-AI
neutral